These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 19484400)

  • 1. Design, synthesis and biological evaluation of non-peptide PAR1 thrombin receptor antagonists based on small bifunctional templates: arginine and phenylalanine side chain groups are keys for receptor activity.
    Androutsou ME; Saifeddine M; Hollenberg MD; Matsoukas J; Agelis G
    Amino Acids; 2010 Apr; 38(4):985-90. PubMed ID: 19484400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities.
    Alexopoulos K; Fatseas P; Melissari E; Vlahakos D; Roumelioti P; Mavromoustakos T; Mihailescu S; Paredes-Carbajal MC; Mascher D; Matsoukas J
    J Med Chem; 2004 Jun; 47(13):3338-52. PubMed ID: 15189031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides.
    Hollenberg MD; Saifeddine M; al-Ani B; Kawabata A
    Can J Physiol Pharmacol; 1997 Jul; 75(7):832-41. PubMed ID: 9315351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes.
    Maryanoff BE; Santulli RJ; McComsey DF; Hoekstra WJ; Hoey K; Smith CE; Addo M; Darrow AL; Andrade-Gordon P
    Arch Biochem Biophys; 2001 Feb; 386(2):195-204. PubMed ID: 11368342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
    Burke FM; Warnock M; Schmaier AH; Mosberg HI
    Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1's tethered ligand.
    Hammes SR; Coughlin SR
    Biochemistry; 1999 Feb; 38(8):2486-93. PubMed ID: 10029543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinase-activated receptor 2 (PAR(2)): development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)- and PAR(2)-derived peptide ligands.
    Al-Ani B; Saifeddine M; Kawabata A; Renaux B; Mokashi S; Hollenberg MD
    J Pharmacol Exp Ther; 1999 Aug; 290(2):753-60. PubMed ID: 10411588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives.
    Thorstensson F; Kvarnström I; Musil D; Nilsson I; Samuelsson B
    J Med Chem; 2003 Mar; 46(7):1165-79. PubMed ID: 12646027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
    Wu CC; Teng CM
    Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.
    Bone R; Lu T; Illig CR; Soll RM; Spurlino JC
    J Med Chem; 1998 Jun; 41(12):2068-75. PubMed ID: 9622548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands.
    Kawabata A; Saifeddine M; Al-Ani B; Leblond L; Hollenberg MD
    J Pharmacol Exp Ther; 1999 Jan; 288(1):358-70. PubMed ID: 9862790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
    Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
    J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
    Bilodeau ML; Hamm HE
    J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
    Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE
    Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics.
    Marinko P; Krbavcic A; Mlinsek G; Solmajer T; Bakija AT; Stegnar M; Stojan J; Kikelj D
    Eur J Med Chem; 2004 Mar; 39(3):257-65. PubMed ID: 15051174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.
    Temple KJ; Duvernay MT; Young SE; Wen W; Wu W; Maeng JG; Blobaum AL; Stauffer SR; Hamm HE; Lindsley CW
    J Med Chem; 2016 Aug; 59(16):7690-5. PubMed ID: 27482618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential roles of two consecutive phenylalanine residues in thrombin receptor-tethered ligand peptides (SFFLRNP) in thrombin receptor activation.
    Shimohigashi Y; Nose T; Okazaki M; Satoh Y; Ohno M; Costa T; Shimizu N; Ogino Y
    Biochem Biophys Res Commun; 1994 Aug; 203(1):366-72. PubMed ID: 8074680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells.
    Hansen KK; Saifeddine M; Hollenberg MD
    Immunology; 2004 Jun; 112(2):183-90. PubMed ID: 15147561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease-activated receptors: development of agonists selective for receptors triggered by either thrombin (PAR1) or trypsin (PAR2).
    Kawabata A; Saifeddine M; al-Ani B; Hollenberg MD
    Proc West Pharmacol Soc; 1997; 40():49-51. PubMed ID: 9436211
    [No Abstract]   [Full Text] [Related]  

  • 20. Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes.
    Pinet C; Algalarrondo V; Sablayrolles S; Le Grand B; Pignier C; Cussac D; Perez M; Hatem SN; Coulombe A
    Mol Pharmacol; 2008 Jun; 73(6):1622-31. PubMed ID: 18326052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.